Eligibility for Anti-Obesity Medications through Medicare for Older Adults with Overweight or Obesity
Chetty A, Khunte M, Chen A, Jastreboff A, Krumholz H, Lu Y. Eligibility for Anti-Obesity Medications through Medicare for Older Adults with Overweight or Obesity. American Heart Journal 2024, 278: 8. DOI: 10.1016/j.ahj.2024.09.022.Peer-Reviewed Original ResearchAnti-obesity medicationsOlder adultsType 2 diabetesNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyCardiovascular diseaseNutrition Examination SurveyOlder ageMale sexExamination SurveyMinority race/ethnicitySociodemographic statusPopulation of beneficiariesMedicare beneficiariesPost-MarchLow-incomeMedicare Part D.Medicare coverageMedicareStudy sampleWhite racePre-marchEligibility ratesObesityPooled dataEligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria
Chetty A, Khunte M, Lu Y, Chen A. Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria. American Heart Journal 2024, 278: 10. DOI: 10.1016/j.ahj.2024.09.026.Peer-Reviewed Original ResearchUS populationNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyPrevention of type 2 diabetesUnder-representation of malesNutrition Examination SurveyPeople of BlackExamination SurveyWaist circumferenceUS adultsHispanic race/ethnicityType 2 diabetesAnti-obesity medicationsDocumented BMIReversion to normoglycemiaStudy sampleNon-medicalWhite raceObesityPrediabetesAdultsBMIMean body weightParticipantsHbA1c